RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. [electronic resource]
Producer: 20161213Description: 111 p. digitalISSN:- 1745-6215
- Anti-Infective Agents -- adverse effects
- Clinical Protocols
- Drug Therapy, Combination
- Duodenum -- drug effects
- Electroencephalography
- Endoscopy, Gastrointestinal
- Evoked Potentials, Visual
- Flicker Fusion
- Gastrointestinal Microbiome -- drug effects
- Germany
- Hepatic Encephalopathy -- diagnosis
- Humans
- Lactulose -- therapeutic use
- Liver Cirrhosis -- complications
- Pilot Projects
- Psychometrics
- Research Design
- Rifamycins -- adverse effects
- Rifaximin
- Stomach -- drug effects
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.